EVMN 10-Q filed 2026-11-12 | Key takeaways
EVMN filed its 10-Q; the most relevant disclosure change is added Subsequent events - Hinova license agreement: In November 2026, the company entered a license agreement with Hinova Pharmaceuticals Inc. for exclusive worldwide rights (excluding Greater China) to EVO570, an oral VAV1 molecular glue degrader, with $20.0M upfront cash payment, $10.0M in pre-funded warrants.
Key takeaways
EVO756 discontinued for CSU and AD: Phase 2b trials for both indications failed to meet primary endpoints; development continues only for migraine with Phase 2b initiated in July 2026 and results expected in H2 2027.
Hinova license agreement: Exclusive worldwide rights (ex-China) for EVO570 VAV1 molecular glue degrader with $20.0M upfront cash, $10.0M in pre-funded warrants, up to $1.1B in potential milestones, and mid single-digit to low double-digit royalties.
November 2026 private placement: 4,966,889 shares at $6.04 per share for gross proceeds of $30.0M.
Subsequent event milestone: $5.0M development milestone payment received in October 2026 from Maruho Greater Asia for EVO756 Phase 2b CSU trial completion.
New pre-clinical program EVO646: Oral TLR 7/8 antagonist with Phase 1 trials planned for H1 2027.
Cash position: $262.3M in cash, cash equivalents, and investments as of September 30, 2026; runway extended into second half of 2029.
New risk factors added: AI-powered solutions risks, China dependency risks for EVO570, U.S.-China regulatory/policy risks, and Hinova dependency risks.
Key metrics
Disclosure changes
- Subsequent events - Hinova license agreement
In November 2026, the company entered a license agreement with Hinova Pharmaceuticals Inc. for exclusive worldwide rights (excluding Greater China) to EVO570, an oral VAV1 molecular glue degrader, with $20.0M upfront cash payment, $10.0M in pre-funded warrants (1,262,413 shares), up to $1.1B in potential development, regulatory, and commercial milestones, and tiered royalties from mid single-digits to low double-digits on net sales.
Major strategic transaction adding a new pre-clinical program with significant milestone and royalty potential; upfront payment and warrant issuance will impact Q4 2026 financials - Subsequent events - November 2026 private placement
In November 2026, the company sold 4,966,889 shares of common stock at $6.04 per share in a private placement for gross proceeds of $30.0M; registration rights agreement was entered for resale of shares.
Capital raise provides additional liquidity; increased share count has dilution impact - Subsequent events - Maruho Greater Asia milestone
In October 2026, completion of the Phase 2b clinical trial of EVO756 in CSU triggered a $5.0M development milestone payment to the company under the Maruho Greater Asia Agreement; payment was due within ten business days and will be recognized as revenue in Q4 2026.
Cash inflow from completed milestone despite EVO756 CSU program discontinuation; Q4 2026 revenue recognition - Clinical development - EVO756 discontinued for CSU and AD
In June 2026, the Phase 2b trial of EVO756 in CSU did not meet its primary endpoint (mean change in UAS7 at 12 weeks); in September 2026, the Phase 2b trial in AD also failed to meet its primary endpoint at any dose; based on these results, the company ceased development of EVO756 for both CSU and AD indications.
Two major clinical setbacks reduce pipeline value; migraine remains the sole active EVO756 indication - Risk factors - new AI risks
New risk factor added regarding use of AI-powered solutions, including regulatory risks (EU AI Act, state laws), compliance costs, potential data leakage, and competitive disadvantages.
Expanded regulatory burden and operational risks from AI adoption - Risk factors - China dependency and U.S.-China policy risks
New risk factors added regarding dependence on Hinova (China-based) for EVO570 technology transfer and supply, U.S. regulatory/trade policy risks affecting China-originated drug development, and limited control over Hinova-conducted clinical trials in China.
Significant geopolitical and operational risks for EVO570 program following Hinova license
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow EVMN in real time
Get material earnings, filing, IR, and earnings-call alerts by email.